Manoj Kumar Sarangi, Dr. K.A Chowdary, Ankush Sundriyal
Assistant Professor, Department of Pharmaceutical Sciences, Sardar Bhagwan Singh PG Institute of Biomedical sciences and Research, Balawala, Dehradun, Uttarakhand, India.Professor, Dept. of Pharmaceutics, Roland Inst. Of Pharmaceutical Sciences, Berhampur, Odisha, India.
Keywords: Bilayer tablets, HPMC K100 & K4, Guar gum, Paracetamol, Tizanidine.

In the present study Paracetamol and Tizanidine were considered as the model drugs for development of bilayer tablets. Paracetamol with the dose 600mg/tablet was considered under the matrix layer and Tizanidine with the dose 2mg/tablet was considered under immediate release layer. The polymers like HPMC (Hydroxy propyl methyl cellulose) K100 & K4 grades, guar gum are used for development of matrix layer. The calibration curve for Paracetamol was plotted by using UV spectroscope at an absorbance of 280 nm as per the method developed by glenmak pharmaceutical ltd. The calibration curve for Tizanidine was plotted by using HPLC at an absorbance of 230nm. The physicochemical parameters of both the matrix tablets of Paracetamol as well as bilayer tablets were carried out. The formulation of sustained release layer was optimized with respect to their dissolution parameters. The dissolution of the bilayer tablets were carried out in 0.1N HCl. The optimized batches showing a release rate more than 90% were considered for development of bilayer tablets. The pharmacokinetic parameters for both the matrix layer formulations of Paracetamol as well as bilayer tablets were conducted with zero order, first order, higuchi and korsemeyer patterns. The optimized formulations were found to be following zero order release kinetics. The accelerated stability study of the optimized formulations (matrix layer and bilayer tablets) were conducted for three months at the conditions of 40oc/75%RH and found to be stable. The FTIR study was conducted for determining drug polymer interaction.

Article Information

Identifiers and Pagination:
First Page:
Last Page:
Publisher Id:19204159.6:4.2014
Article History:
Received:June 20, 2014
Accepted:July 10, 2014
Collection year:2014
First Published:October 1, 2014

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885